Inloggad som:
FLIRT-studien
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
FLIRT-studien
Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 randomization to tafasitamab for low-risk disease: a phase II study – NLG-FLIRT
Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 randomization to tafasitamab for low-risk disease: a phase II study – NLG-FLIRT
PLACEHOLDER
En öppen fas II-studie med rituximab-lenalidomid-tafasitamab mot högrisksjukdom och rituximab-lenalidomid med randomisering till tafasitamab mot lågrisksjukdom. Det är planerat att inkludera 270 patienter i Norden
Mer information om studien för vårdgivare
Histologically confirmed follicular lymphoma (not grade 3B) stage II-IV not suitable for radiotherapy (preferably a surgical biopsy, core but not fine needle acceptable)
At least one two-dimensionally measurable lesion with a longest diameter > 15 mm
CD20-negative or CD19-negative lymphoma
Transformation to aggressive lymphoma including grade 3B at any timepoint before starting treatment
CNS involvement
Behandling
Fas 3
Ej tillämpbar
Akademisk
Studien ändrades senast: (2025-08-27)